{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:21:35Z","timestamp":1770232895384,"version":"3.49.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.amjmed.2023.10.028","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:39:47Z","timestamp":1700512787000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lifestyle Approach and Medical Therapy of Lower Extremity Peripheral Artery Disease"],"prefix":"10.1016","volume":"137","author":[{"given":"Chayakrit","family":"Krittanawong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johao","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafeez Ul Hassan","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahboob","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K M Venkat","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.amjmed.2023.10.028_bib0001","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"issue":"3 suppl","key":"10.1016\/j.amjmed.2023.10.028_bib0002","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.028_bib0003","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Fowkes","year":"2008","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.amjmed.2023.10.028_bib0005","first-page":"e1020","article-title":"High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease","volume":"7","author":"Jones","year":"2019","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0006","first-page":"809","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"165","author":"Song","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0007","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.113.01925","article-title":"Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study","volume":"63","author":"Garg","year":"2014","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/clc.4960260208","article-title":"C-reactive protein and rapidly progressive coronary artery disease\u2013is there any relation?","volume":"26","author":"Zairis","year":"2003","journal-title":"Clin Cardiol"},{"issue":"13","key":"10.1016\/j.amjmed.2023.10.028_bib0010","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/01.CIR.0000142664.18739.92","article-title":"Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris","volume":"110","author":"Zouridakis","year":"2004","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.amjmed.2023.10.028_bib0011","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.CIR.0000163569.97918.C0","article-title":"Inflammation and Carotid Artery\u2014Risk for Atherosclerosis Study (ICARAS)","volume":"111","author":"Schillinger","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.028_bib0012","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1161\/CIRCULATIONAHA.106.683722","article-title":"Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies","volume":"116","author":"Wilson","year":"2007","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.amjmed.2023.10.028_bib0013","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.1997.03540460039030","article-title":"Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project","volume":"277","author":"Graham","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000803","article-title":"\u03b22-Microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease","volume":"3","author":"Joosten","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.028_bib0015","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.amjcard.2011.01.007","article-title":"Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease","volume":"107","author":"McDermott","year":"2011","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamacardio.2021.3987","article-title":"Smoking cessation improves outcomes in patients with peripheral artery disease","volume":"7","author":"Creager","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0017","first-page":"560","article-title":"Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease","volume":"38","author":"Abramson","year":"2022","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1358863X18779694","article-title":"E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: a randomized, double-blinded pilot study","volume":"23","author":"Franzen","year":"2018","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2007.12.238","article-title":"Depressive symptoms in peripheral arterial disease: a follow-up study on prevalence, stability, and risk factors","volume":"110","author":"Smolderen","year":"2008","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jvs.2006.11.057","article-title":"Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization","volume":"45","author":"Cherr","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2020.109963","article-title":"Mental health concerns in patients with symptomatic peripheral artery disease: insights from the PORTRAIT registry","volume":"131","author":"Thomas","year":"2020","journal-title":"J Psychosom Res"},{"issue":"7","key":"10.1016\/j.amjmed.2023.10.028_bib0022","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4239\/wjd.v6.i7.961","article-title":"Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes","volume":"6","author":"Thiruvoipati","year":"2015","journal-title":"World J Diabetes"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0023","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0024","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jamcollsurg.2018.09.021","article-title":"Effect of intensive glycemic control on risk of lower extremity amputation","volume":"227","author":"Goldman","year":"2018","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","article-title":"The residual cardiorenal risk in type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.amjmed.2023.10.028_bib0026","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0027","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12933-021-01306-6","article-title":"Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.028_bib0028","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109076","article-title":"Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study","volume":"180","author":"Hsiao","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0030","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jvs.2008.05.014","article-title":"Nutrition impacts the prevalence of peripheral arterial disease in the United States","volume":"48","author":"Lane","year":"2008","journal-title":"J Vasc Surg"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0031","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1358863X19867393","article-title":"Healthy diet and fiber intake are associated with decreased risk of incident symptomatic peripheral artery disease - a prospective cohort study","volume":"24","author":"Kulezic","year":"2019","journal-title":"Vasc Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0032","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.amjmed.2023.10.028_bib0033","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0034","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jama.2013.280618","article-title":"Association of Mediterranean diet with peripheral artery disease: the PREDIMED Randomized Trial","volume":"311","author":"Ruiz-Canela","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11883-003-0039-5","article-title":"The DASH diet and blood pressure","volume":"5","author":"Craddick","year":"2003","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0036","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/advances\/nmaa041","article-title":"Dietary Approaches to Stop Hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Filippou","year":"2020","journal-title":"Adv Nutr"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0037","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","article-title":"Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease","volume":"55","author":"Bavry","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0038","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jvs.2013.10.084","article-title":"Walking disability in patients with peripheral artery disease is associated with arterial endothelial function","volume":"59","author":"Grenon","year":"2014","journal-title":"J Vasc Surg"},{"issue":"7","key":"10.1016\/j.amjmed.2023.10.028_bib0039","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jacc.2009.01.080","article-title":"Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism","volume":"54","author":"Anderson","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.mayocpiqo.2023.08.004","article-title":"Exercise therapy in the management of peripheral arterial disease","volume":"7","author":"Hallak","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"12","key":"10.1016\/j.amjmed.2023.10.028_bib0041","article-title":"Exercise for intermittent claudication","volume":"12","author":"Lane","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0042","article-title":"Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication","volume":"4","author":"Hageman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.028_bib0043","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/bjs.9207","article-title":"Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial","volume":"100","author":"Fakhry","year":"2013","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0044","first-page":"64","article-title":"Nutritional status of patients admitted to a metropolitan tertiary care vascular surgery unit","volume":"28","author":"Thomas","year":"2016","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2015.12.034","article-title":"Obesity and peripheral arterial disease: a Mendelian randomization analysis","volume":"247","author":"Huang","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.028_bib0046","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.orcp.2023.05.002","article-title":"Obesity prevalence and variability in management practices for patients with symptomatic peripheral artery disease","volume":"17","author":"Scierka","year":"2023","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0047","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/fca-2017-0038","article-title":"Intermittent fasting and cardiovascular disease: current evidence and unresolved questions","volume":"14","author":"Tinsley","year":"2018","journal-title":"Future Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0048","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/gerona\/gls092","article-title":"Fat mass loss predicts gain in physical function with intentional weight loss in older adults","volume":"68","author":"Beavers","year":"2013","journal-title":"J Gerontol Series A Biol Sci Med Sci"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0049","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JMDH.S33625","article-title":"A 3-year follow-up study of inpatients with lower limb ulcers: evidence of an obesity paradox?","volume":"5","author":"Miller","year":"2012","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0050","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.clnu.2018.09.031","article-title":"Obesity paradox in peripheral artery disease","volume":"38","author":"Keller","year":"2019","journal-title":"Clin Nutr"},{"issue":"9841","key":"10.1016\/j.amjmed.2023.10.028_bib0051","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0052","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jvs.2013.06.069","article-title":"Statin use and lower extremity amputation risk in nonelderly diabetic patients","volume":"58","author":"Sohn","year":"2013","journal-title":"J Vasc Surg"},{"issue":"7","key":"10.1016\/j.amjmed.2023.10.028_bib0053","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1210\/jc.2016-3717","article-title":"Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease","volume":"102","author":"Hsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.amjmed.2023.10.028_bib0054","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.amjmed.2023.10.028_bib0056","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.amjmed.2023.10.028_bib0057","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0058","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.amjmed.2023.10.028_bib0059","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"10.1016\/j.amjmed.2023.10.028_bib0061","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0062","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3390\/ijms23042104","article-title":"Omega-3 polyunsaturated fatty acids-vascular and cardiac effects on the cellular and molecular level (narrative review)","volume":"23","author":"Drenjan\u010devi\u0107","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0063","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2013.10.006","article-title":"Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases","volume":"19","author":"Spite","year":"2014","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0064","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of Omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0066","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pcad.2021.11.002","article-title":"Impressive results with EPA, but EPA\/DHA combinations also reduce cardiovascular outcomes","volume":"69","author":"Lavie","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0067","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/nu13010204","article-title":"An update on Omega-3 polyunsaturated fatty acids and cardiovascular health","volume":"13","author":"Elagizi","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.amjmed.2023.10.028_bib0068","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.mayocp.2021.03.004","article-title":"Omega-3 benefits remain strong post-STRENGTH","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.amjmed.2023.10.028_bib0069","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"10235","key":"10.1016\/j.amjmed.2023.10.028_bib0070","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/S0140-6736(20)30799-6","article-title":"Aspirin for secondary prevention of cardiovascular disease","volume":"395","author":"Byrne","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.amjmed.2023.10.028_bib0071","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2023.10.028_bib0072","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.amjmed.2023.10.028_bib0073","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","article-title":"Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","volume":"261","author":"Catalano","year":"2007","journal-title":"J Intern Med."},{"issue":"7","key":"10.1016\/j.amjmed.2023.10.028_bib0074","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"9038","key":"10.1016\/j.amjmed.2023.10.028_bib0075","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0076","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/phar.2758","article-title":"Pharmacogenetics of P2Y12 receptor inhibitors","volume":"43","author":"Thomas","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"15","key":"10.1016\/j.amjmed.2023.10.028_bib0077","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.3390\/ijerph19158977","article-title":"Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status","volume":"19","author":"Pradhan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.amjmed.2023.10.028_bib0078","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","article-title":"Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0079","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2023.10.028_bib0080","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.amjmed.2023.10.028_bib0081","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jcin.2016.07.034","article-title":"Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2\u00b0P\u2013TIMI 50 trial","volume":"9","author":"Bonaca","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.amjmed.2023.10.028_bib0082","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0083","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1345\/aph.19408","article-title":"Cilostazol: treatment of intermittent claudication","volume":"35","author":"Reilly","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"16","key":"10.1016\/j.amjmed.2023.10.028_bib0084","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.10.028_bib0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.amjmed.2023.10.028_bib0086","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.10.028_bib0087","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432300709X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432300709X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:30:51Z","timestamp":1757583051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293432300709X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S000293432300709X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.10.028","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifestyle Approach and Medical Therapy of Lower Extremity Peripheral Artery Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}